AbbVie has submitted applications for a new indication for upadacitinib (RINVOQ) for the treatment of patients living with ...

AbbVie has submitted applications to the FDA and EMA for new indications for upadacitinib (RINVOQ 15-mg) for the treatment of adult and adolescent patients living with non-segmental vitiligo (NSV), ...

Studies evaluating the oral JAK inhibitor in adults and adolescents with non-segmental vitiligo are submitted for approval of the expanded indication.

AbbVie (NYSE: ABBV) today announced that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for upadacitinib (RINVOQ® ...

Ruxolitinib phosphate cream is the first and only drug approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for repigmentation in nonsegmental vitiligo [1,2] ...

AbbVie Inc. stays a Strong Buy after a Q4 2025 earnings beat led by HUMIRA, plus growth in immunology and neuroscience. Click ...

AbbVie on Tuesday said the applications with the U.S. Food and Drug Administration and the European Medicines Agency cover Rinvoq for the treatment of adults and adolescents with non-segmental ...

AbbVie has submitted regulatory applications in the US and Europe for Rinvoq as a potential first systemic therapy for non segmental vitiligo. The filing seeks to expand Rinvoq's use beyond its ...

Dublin, Jan. 26, 2026 (GLOBE NEWSWIRE) -- The "Vitiligo Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ResearchAndMarkets.com's ...

Mamta Mohandas' acting career began with a commercially unsuccessful debut, but she found recognition with 'Big B' and ...